Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014, Article ID 704371, 7 pages
http://dx.doi.org/10.1155/2014/704371
Case Report

36-Year-Old Female with Catastrophic Antiphospholipid Syndrome Treated with Eculizumab: A Case Report and Review of Literature

Department of Hematology and Oncology, Jacobi Medical Center Affiliate of Albert Einstein College of Medicine, 1400 Pelham Parkway, Bronx, NY 10461, USA

Received 16 July 2014; Accepted 8 September 2014; Published 15 October 2014

Academic Editor: Akimichi Ohsaka

Copyright © 2014 Marianna Strakhan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Cervera, J.-C. Piette, J. Font et al., “Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients,” Arthritis and Rheumatism, vol. 46, no. 4, pp. 1019–1027, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Asherson, G. Espinosa, S. Menahem et al., “Relapsing catastrophic antiphospholipid syndrome: report of three cases,” Seminars in Arthritis and Rheumatism, vol. 37, no. 6, pp. 366–372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Sciascia, C. Lopez-Pedrera, D. Roccatello, and M. J. Cuadrado, “Catastrophic antiphospholipid syndrome (CAPS),” Best Practice and Research: Clinical Rheumatology, vol. 26, no. 4, pp. 535–541, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. R. A. Asherson, R. Cervera, J.-C. Piette et al., “Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients,” Medicine, vol. 77, no. 3, pp. 195–207, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Cervera, J. Font, J. A. Gómez-Puerta et al., “Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome,” Annals of the Rheumatic Diseases, vol. 64, no. 8, pp. 1205–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Cervera, S. Bucciarelli, M. A. Plasín et al., “Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 240–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Asherson, “The catastrophic antiphospholipid (Asherson's) syndrome,” Autoimmunity Reviews, vol. 6, no. 2, pp. 64–67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Giannakopoulos and S. A. Krilis, “The pathogenesis of the antiphospholipid syndrome,” The New England Journal of Medicine, vol. 368, no. 11, pp. 1033–1044, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Pengo, A. Tripodi, G. Reber et al., “Update of the guidelines for lupus anticoagulant detection,” Journal of Thrombosis and Haemostasis, vol. 7, no. 10, pp. 1737–1740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Cervera, “Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome,” Current Rheumatology Reports, vol. 12, no. 1, pp. 70–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Espinosa, H. Berman, and R. Cervera, “Management of refractory cases of catastrophic antiphospholipid syndrome,” Autoimmunity Reviews, vol. 10, no. 11, pp. 664–668, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Berman, I. Rodríguez-Pintó, R. Cervera et al., “Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab,” Autoimmunity Reviews, vol. 12, no. 11, pp. 1085–1090, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Shapira, D. Andrade, S. L. Allen, and J. E. Salmon, “Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab,” Arthritis and Rheumatism, vol. 64, no. 8, pp. 2719–2723, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. B. E. Lonze, A. L. Singer, and R. A. Montgomery, “Eculizumab and renal transplantation in a patient with CAPS,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1744–1745, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Canaud, N. Kamar, D. Anglicheau et al., “Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes,” The American Journal of Transplantation, vol. 13, no. 8, pp. 2179–2185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. B. E. Lonze, A. A. Zachary, C. M. Magro et al., “Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation,” The American Journal of Transplantation, vol. 14, no. 2, pp. 459–465, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Salvadori and E. Bertoni, “Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations,” World Journal of Nephrology, vol. 2, no. 3, pp. 56–76, 2013. View at Publisher · View at Google Scholar
  19. V. Michael Holers, G. Girardi, L. Mo et al., “Complement C3 activation is required for antiphospholipid antibody-induced fetal loss,” Journal of Experimental Medicine, vol. 195, no. 2, pp. 211–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Girardi, J. Berman, P. Redecha et al., “Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome,” Journal of Clinical Investigation, vol. 112, no. 11, pp. 1644–1654, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Fischetti, P. Durigutto, V. Pellis et al., “Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor,” Blood, vol. 106, no. 7, pp. 2340–2346, 2005. View at Publisher · View at Google Scholar · View at Scopus